Navigation Links
Surgery without stitches
Date:12/21/2007

A thin polymer bio-film that seals surgical wounds could make sutures a relic of medical history.

Measuring just 50 microns thick, the film is placed on a surgical wound and exposed to an infrared laser, which heats the film just enough to meld it and the tissue, thus perfectly sealing the wound.

Known as Surgilux, the devices raw material is extracted from crab shells and has Food and Drug Administration approval in the US.

Early test results indicate that it has strongest potential for use in brain and nerve surgery because it can avoid the numerous disadvantages of invasive stictches/sutures, which fail to seal and can act as a source of infection.

Up to 11% of brain surgery patients have to return for repeat surgery due to leakage of cerebro-spinal fluid (CSF) and other complications arising from sutures.

Surgical sutures date back some 4,000 years, so a new approach is long overdue, according to one of the devices inventors and leader of the Bio/polymer Research Group, UNSW scientist John Foster.

Others have tried surgical glues but these are mainly gel-like so bonding to the tissue is uneven often resulting in leakages and theyre not easy to use. The strongest surgical glue is so toxic that its limited to external applications, says Dr Foster. Other devices use ultra-violet light to effect rather poor sealing, but UV rays are damaging to living cells

The beauty of this is that infra-red laser doesnt cause any tissue damage. Better still, Surgilux has anti-microbial properties, which deters post-operative infections.

Foster and his team are working with micro-surgeon Marcus Stoodley who specialises in nerve repair. Based at the Prince of Wales Hospital Stoodley is excited about early test results.

Surgilux is well suited to repairing damaged nerves because the gold standard -- sutures inevitably cause damage to nerves and there is always some permanent loss of function.

Our test results with rats have shown some degree of permanent nerve recovery within six weeks of operating.

The researchers who are looking for commercial backing to initiate clinical trials are planning a second generation version of Surgilux that incorporates growth factors and perhaps stem cells to regenerate nerves.


'/>"/>

Contact: Dan Gaffney
d.gaffney@unsw.edu.au
61-411-156-015
University of New South Wales
Source:Eurekalert

Related biology news :

1. Minimally invasive heart surgery research wins NIH award
2. Pennsylvania Hospital surgeon receives grant to develop molecular cardiac surgery
3. BMI criteria for obesity surgery should be lowered, UT Southwestern researcher suggests
4. Neuronal conduction of excitation without action potentials based on ceramide production
5. The benefits of 80 million years without sex
6. Coral reefs will be permanently damaged without urgent action
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/17/2017)... 2017 NXT-ID, Inc. (NASDAQ: NXTD ) ... of its 2016 Annual Report on Form 10-K on Thursday April ... ... in the Investor Relations section of the Company,s website at ... at http://www.sec.gov . 2016 Year Highlights: ...
(Date:4/11/2017)... April 11, 2017 Crossmatch®, a globally-recognized ... solutions, today announced that it has been awarded ... Projects Activity (IARPA) to develop next-generation Presentation Attack ... "Innovation has been a driving force within ... will allow us to innovate and develop new ...
(Date:4/11/2017)... NXT-ID, Inc. (NASDAQ:   NXTD ) ... appointment of independent Directors Mr. Robin D. Richards ... Directors, furthering the company,s corporate governance and expertise. ... Gino Pereira , Chief Executive ... their guidance and benefiting from their considerable expertise as we ...
Breaking Biology News(10 mins):
(Date:9/17/2017)... , ... September 17, 2017 , ... ... the South Korean Ministry of Food and Drug Safety (KMFDS) for an Investigational ... against the Middle East Respiratory Syndrome coronavirus (MERS-CoV). The study in Korea represents ...
(Date:9/14/2017)... ... September 14, 2017 , ... ... launch of its CliniControl™ (CC) product portfolio, clinically-relevant starting and ancillary materials ... of human Mesenchymal Stem/Stromal Cell (hMSC)-based therapies. The CliniControl product portfolio will ...
(Date:9/14/2017)... ... September 14, 2017 , ... AIM Global, the worldwide standards agency for ... won the 2017 Case Study Competition for AIDC. The award is given to ... risk” and push the adoption of automated data collection systems further. The TRACTUS ...
(Date:9/12/2017)... ... September 12, 2017 , ... PhysIQ, a Chicago-based company ... ambulatory patient monitoring and clinical trial support, earned DPharm Idol 2017 honors at ... , Launched in 2005, PhysIQ leverages artificial intelligence (AI) to empower digital ...
Breaking Biology Technology: